By Chris Wack
ReShape Lifesciences Inc. shares rose 33% to 64 cents a share after the company said it received U.S. Food and Drug Administration 510(k) clearance for its disposable gastro intestinal balloon indicator calibration tube for use in gastric and bariatric surgical procedures.
The company said it expects U.S. commercial sales to begin in September 2022.
The product includes three new sizes for bariatric procedures such as laparoscopic sleeve gastrectomy, gastric bypass and adjustable gastric banding.
The stock hit its 52-week low of 46 cents a share July 27.
Write to Chris Wack at firstname.lastname@example.org
(END) Dow Jones Newswires
August 10, 2022 12:40 ET (16:40 GMT)Copyright (c) 2022 Dow Jones & Company, Inc.